← Eichor
Condition: Atopic Dermatitis Ad Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Atopic Dermatitis Ad

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Phase 2 Randomized Double-blind Study to Assess Topical Zabalafin Hydrogel Vs Vehicle in Mild to Moderate AD.
Phase 2 · 12 location(s) · Alphyn Biologics · NCT06855745Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
Phase 2 · 23 location(s) · Enveda Therapeutics · NCT07298395A Phase I Study of SSGJ-716 in Healthy Adults and Participants With Moderate-to-Severe Atopic Dermatitis
Phase 1 · 1 location(s) · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · NCT07693738A Phase 1 Clinical Study Comparing GS101 and Dupixent® After Subcutaneous Injection
Phase 1 · 1 location(s) · Jiangsu Genscend Biopharmaceutical Co., Ltd · NCT07411755A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moder
Phase 2 · 2 location(s) · AbbVie · NCT06524635A Long-term Safety and Efficacy Study Evaluating CM512 in Atopic Dermatitis.
Phase 2 · 1 location(s) · Keymed Biosciences Co.Ltd · NCT07230483CorEvitas International Adolescent Atopic Dermatitis (AD) Drug Safety and Effectiveness Registry
Phase N/A · 1 location(s) · CorEvitas · NCT06238765A Clinical Study to Evaluate SM17 for Atopic Dermatitis
Phase 2 · 1 location(s) · SinoMab BioScience Ltd · NCT07445919A Study to Learn About the Study Medicine (Called Cibinqo) in People With Atopic Dermatitis
Phase N/A · 1 location(s) · Pfizer · NCT05391061A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis.
Phase N/A · 30 location(s) · Pfizer · NCT05689151Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
Phase 1 · 1 location(s) · Arcutis Biotherapeutics, Inc. · NCT07453602A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis
Phase 1 · 14 location(s) · Sitryx Therapeutics Ltd · NCT07558668Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic Dermatitis
Phase 3 · 3 location(s) · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · NCT07042126Skin Microbial Ecology in Atopic Dermatitis
Phase N/A · 1 location(s) · University of Rochester · NCT04170244The Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis
Phase 1 · 2 location(s) · Daniel Kaplan · NCT06928246An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
Phase N/A · 1 location(s) · Regeneron Pharmaceuticals · NCT03936335Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease
Phase 1 · 2 location(s) · Seismic Therapeutic AU Pty Ltd · NCT07455578CeraVe Effect on Restoring Skin Hydration as Maintenance Regimen in Subjects With Mild to Moderate Atopic Dermatitis
NA · 1 location(s) · Societa Italiana di Dermatologia Medica, Chirurgica, Estetic · NCT07204561Evaluation of Efficacy and Safety of Oral Roflumilast for Treatment of Moderate to Severe Atopic Dermatitis in Patients
Phase 2 · 1 location(s) · Nora Mohamed Abdelrazik · NCT07297602Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD
Phase 2 · 1 location(s) · Corvus Pharmaceuticals, Inc. · NCT07441395A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis
Phase 2 · 88 location(s) · Bluefin Biomedicine, Inc. · NCT07105488Effect of an Emollient Cream Containing a Milk Bioactive Peptide on Clinical Signs, Pruritus and Bacterial Colonization
NA · 1 location(s) · Universidad Autónoma de Aguascalientes · NCT07259343A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subject
Phase 2 · 1 location(s) · Turn Therapeutics · NCT07355075A Phase 1/1b Study to Evaluate Safety, Tolerability and Pharmacokinetics of ZL-1503 in Healthy Volunteers and Participan
Phase 1 · 1 location(s) · Zai Lab (Shanghai) Co., Ltd. · NCT07235384A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Moderate to Severe Atopic Dermatitis (AD)
Phase 1 · 10 location(s) · Bambusa Therapeutics · NCT07239947A First-in-human Study to Investigate Single Doses of DCY636 in Healthy Volunteers and Multiple Doses in Participants Wi
Phase 1 · 1 location(s) · Novartis Pharmaceuticals · NCT07604324Global Healthcare Study on Atopic Dermatitis
Phase N/A · 1 location(s) · Julia Tatjana Maul · NCT07659756A Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD)
Phase 1 · 14 location(s) · Bambusa Therapeutics · NCT06808477Treatment of AD With IgE Specific Immunoadsorption (IGEIAAD)
Phase 2 · 1 location(s) · Universitaire Ziekenhuizen KU Leuven · NCT02365246SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)
Phase N/A · 8 location(s) · Leiden University Medical Center · NCT07021495
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.